MEDICAMEN BIOTECH
|
MEDICAMEN BIOTECH Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 11.64 | 12.19 | 9.93 | 10.88 | 10.28 |
| CEPS(Rs) | 16.67 | 16.92 | 11.99 | 12.93 | 12.17 |
| DPS(Rs) | 1.00 | 1.00 | 1.00 | 0.50 | 1.00 |
| Book NAV/Share(Rs) | 147.21 | 113.56 | 103.33 | 97.55 | 73.69 |
| Tax Rate(%) | 13.59 | 17.67 | 26.01 | 26.08 | 31.37 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 17.28 | 20.86 | 17.45 | 15.52 | 14.24 |
| EBIT Margin(%) | 14.51 | 17.36 | 15.89 | 15.07 | 15.42 |
| Pre Tax Margin(%) | 12.10 | 15.67 | 14.54 | 14.33 | 14.29 |
| PAT Margin (%) | 10.46 | 12.90 | 10.76 | 10.59 | 9.81 |
| Cash Profit Margin (%) | 14.98 | 17.90 | 13.00 | 12.58 | 11.61 |
| Performance Ratios | |||||
| ROA(%) | 5.87 | 7.11 | 6.46 | 8.36 | 8.80 |
| ROE(%) | 9.06 | 11.25 | 9.89 | 12.94 | 13.95 |
| ROCE(%) | 10.86 | 12.94 | 12.99 | 16.54 | 19.30 |
| Asset Turnover(x) | 0.56 | 0.55 | 0.60 | 0.79 | 0.90 |
| Sales/Fixed Asset(x) | 1.11 | 0.96 | 1.30 | 2.41 | 2.63 |
| Working Capital/Sales(x) | 1.74 | 2.29 | 2.64 | 2.63 | 2.57 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.90 | 1.04 | 0.77 | 0.42 | 0.38 |
| Receivable days | 166.45 | 183.01 | 165.97 | 135.71 | 129.12 |
| Inventory Days | 93.37 | 50.92 | 35.88 | 46.85 | 45.43 |
| Payable days | 311.49 | 316.67 | 253.69 | 189.02 | 161.09 |
| Valuation Parameters | |||||
| PER(x) | 56.31 | 52.79 | 53.78 | 16.61 | 47.18 |
| PCE(x) | 39.31 | 38.05 | 44.53 | 13.98 | 39.84 |
| Price/Book(x) | 4.45 | 5.67 | 5.17 | 1.85 | 6.58 |
| Yield(%) | 0.15 | 0.16 | 0.19 | 0.28 | 0.21 |
| EV/Net Sales(x) | 5.92 | 7.00 | 5.92 | 1.83 | 4.65 |
| EV/Core EBITDA(x) | 31.13 | 31.32 | 32.67 | 10.70 | 27.02 |
| EV/EBIT(x) | 40.82 | 40.35 | 37.27 | 12.12 | 30.18 |
| EV/CE(x) | 3.02 | 3.59 | 3.44 | 1.26 | 4.18 |
| M Cap / Sales | 5.89 | 6.81 | 5.79 | 1.76 | 4.63 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 22.02 | 2.42 | -10.19 | 2.36 | - |
| Core EBITDA Growth(%) | 3.86 | 26.35 | -4.60 | 1.38 | - |
| EBIT Growth(%) | 2.00 | 11.90 | -5.32 | 0.04 | - |
| PAT Growth(%) | -1.14 | 22.82 | -8.74 | 10.52 | - |
| EPS Growth(%) | -4.53 | 22.82 | -8.74 | 5.85 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.14 | 0.19 | 0.15 | 0.10 | 0.14 |
| Current Ratio(x) | 1.98 | 1.69 | 1.80 | 1.84 | 1.98 |
| Quick Ratio(x) | 1.50 | 1.36 | 1.70 | 1.54 | 1.67 |
| Interest Cover(x) | 6.03 | 10.32 | 11.85 | 20.30 | 13.68 |
| Total Debt/Mcap(x) | 0.03 | 0.03 | 0.03 | 0.05 | 0.02 |
Compare Financial Ratios of peers of MEDICAMEN BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MEDICAMEN BIOTECH | ₹531.7 Cr | 1.7% | -21.3% | -34% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹368,766.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹111,102.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,958.0 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹99,939.6 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,104.2 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
MEDICAMEN BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MEDICAMEN BIOTECH | 1.7% |
-21.3% |
-34% |
| SENSEX | -2.4% |
-1% |
21.3% |
You may also like the below Video Courses
